EUCTR2018-000746-19-GB进行中（未招募）1 期
An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials - ECZTEND
EO Pharma A/S0 个研究点目标入组 1,600 人开始时间: 2018年8月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated informed consent has been obtained prior to any protocol-related procedures. Signed and dated informed consent for adolescent subjects must be provided by the subject’s legal representative(s) and by the subject in the form of a signed and dated informed assent (as applicable according to national laws or regulations).
- •2. Subjects must have completed* the treatment period(s) of one of the parent trials: LP0162-1325, -1326, -1334, -1339, -1341, -1342, or-1343, -1346, or TRA-WEI-0015-I.
- •3. Subjects must have complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator.
- •4. Subjects must be able and willing to self-administer tralokinumab treatment (or have it administered by a caregiver) at home after the initial 3 injection visits at the trial site (in this trial).
- •5. Subjects must have applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days prior to baseline.
- •6. Female subjects of childbearing potential (defined as Tanner stage =3 or menarche)* must use a highly effective** form of birth control (confirmed by the investigator) continuously for at least 1 month prior to the pregnancy test at baseline (Week 0), throughout the trial, and for at least 16 weeks (5 half lives of the IMP) after the last administration of IMP.
- •* A female subject is defined as not being of childbearing potential if she is:
- •Postmenopausal (at least 12 months with no menses without an alternative medical cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
- •Premenarchal-
- •**A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is in line with the preferred and usual life style of the subject), same sex partner, or vasectomised partner (given that the subject is monogamous).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1510
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1.Any condition that required permanent discontinuation of trial treatment in the parent trial
- •2.More than 26 weeks have elapsed since the subject received the last IMP injection in the parent trial
- •3.Subjects who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to tralokinumab by the investigator
- •4.Subjects who, during their participation in the parent trial, developed an AE that was deemed related to tralokinumab by the investigator and led to temporary discontinuation of trial treatment, which in the opinion of the investigator could indicate that continued treatment with tralokinumab may present an unreasonable safety risk for the subject
- •5.Receipt of any marketed biological therapy or investigational biologic agent (other than tralokinumab), including immunoglobulin, anti-IgE, or dupilumab:
- •Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer
- •Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline
- •6.Treatment with the following medications within 5 half-lives prior to baseline:
- •Systemic immunosuppressive/immunomodulating drugs (for example, methotrexate, cyclosporine, azathioprine, mycophenolate-mofetil, Janus kinase inhibitors)
- •Systemic corticosteroids (excluding topical, ophthalmic, inhaled, or intranasal delivery)
- •7.Treatment with topical PDE-4 inhibitors or topical JAK inhibitors within 2 weeks prior to baseline
- •8.Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb are eligible provided they are vaccinated against hepatitis B and have negative HBsAg and HBcAb
- •9.Known or suspected hypersensitivity to any component(s) of the IMP
- •10.History of anaphylaxis following any biological therapy
- •11.History of immune complex disease
- •12.History of cancer:
- •Subjects who have had basal cell carcinoma, localised squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date when informed consent was obtained
- •Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date when informed consent was obtained
- •13.Tuberculosis requiring treatment within 12 months prior to screening
- •14.History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history or subject’s verbal report
- •15.Current participation in any other interventional clinical trial, except for tralokinumab trials LP0162-1325, 1326, 1334, 1339, 1341, 1342, 1346, 1343, or TRA-WEI-0015-I
- •17.Receipt of live attenuated vaccines 30 days prior to baseline and during the trial including the safety follow-up period
- •18.Receipt of blood products within 4 weeks of baseline
- •19.Major surgery within 8 weeks prior to baseline, or planned in-patient surgery or hospitalisation during the trial
- •20.History of subject or subject’s legal representative(s) of chronic alcohol or drug abuse within 12 months prior to screening, or any condition (e.g., psychotic state, language
研究者
相似试验
进行中（未招募）
1 期
ong-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTENDMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2018-000746-19-PLEO Pharma A/S1,600
进行中（未招募）
1 期
ong-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTENDMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2018-000746-19-ESEO Pharma A/S1,125
进行中（未招募）
1 期
ong-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTENDAtopic DermatitisEUCTR2018-000746-19-ITEO PHARMA A/S1,500
进行中（未招募）
1 期
ong-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTENDMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2018-000746-19-CZEO Pharma A/S1,600
进行中（未招募）
1 期
ong-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTENDMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2018-000746-19-BEEO Pharma A/S1,600